checkAd
    Startseite > Aktien > Enlivex Therapeutics > Nachrichten
    Enlivex Therapeutics Aktie
    1,2300
     
    EUR
    0,00 %
    0,0000 EUR
    Letzter Kurs 31.05.24 Tradegate
    1,1900
     
    EUR
    1.690 STK
    Geldkurs 31.05.24
    1,2700
     
    EUR
    1.564 STK
    Briefkurs 31.05.24
    ISIN: IL0011319527 · WKN: A119KH · SYM: 1BT · Israel

    Neueste Nachrichten

    Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering
    29.05.24 · globenewswire · Enlivex Therapeutics
    Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering
    28.05.24 · globenewswire · Enlivex Therapeutics
    Enlivex CEO Issues Letter to Shareholders – Perspectives on Recent Events
    29.04.24 · globenewswire · Enlivex Therapeutics
    Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis
    22.04.24 · globenewswire · Enlivex Therapeutics
    Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis
    16.04.24 · globenewswire · Enlivex Therapeutics
    Enlivex to Host Webcast on April 12, 2024 at 8: 30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra In Patients with Sepsis
    11.04.24 · globenewswire · Enlivex Therapeutics
    Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis
    11.04.24 · globenewswire · Enlivex Therapeutics
    Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method
    07.02.24 · globenewswire · Enlivex Therapeutics
    Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis
    17.01.24 · globenewswire · Enlivex Therapeutics
    Enlivex Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis
    20.12.23 · globenewswire · Enlivex Therapeutics
    Enlivex Announces Reprioritization Plan and Second Quarter 2023 Financial Results
    11.09.23 · globenewswire · Enlivex Therapeutics
    Enlivex to Present at the H.C. Wainwright 25th Annual Global Investment Conference
    07.09.23 · globenewswire · Enlivex Therapeutics